Transcripta Bio and Mayo Clinic Partner to Study ALS
The organizations are collaborating to identify new therapeutic targets for ALS using patient-derived molecular data.
Updated on Oct. 16, 2026 in Biotech
Live Poll
Should medical research prioritize AI-driven drug discovery for rare neurodegenerative diseases?
Transcripta Bio and Mayo Clinic have entered a research and licensing agreement to study Amyotrophic Lateral Sclerosis (ALS). The partnership aims to discover new drug candidates by analyzing genetic profiles and molecular data from living patients.
Why it matters
The study seeks to address the complexity of ALS by mapping molecular signatures from patients with sporadic and familial forms of the disease. Researchers hope these insights will accelerate the development of targeted therapies for patients currently facing limited treatment options.
Researchers are utilizing single-cell RNA sequencing on donated patient tissue to compare disease signatures against existing drug-response data. The process leverages a transcriptomic drug-discovery platform to nominate new intervention targets.
The players
Transcripta Bio
Headquartered in Palo Alto, California, this biotech firm focuses on discovery programs for conditions including ASD, FSHD, Huntington's Disease, and Myotonic Dystrophy.
Mayo Clinic
This medical research organization is currently recruiting living ALS patients to provide tissue for the joint study.
Merck & Co
This global pharmaceutical company entered a separate research collaboration with Mayo Clinic earlier this year.
The details
The study includes patients with sporadic and familial ALS, specifically targeting profiles associated with C9orf72, FUS, SOD1, and TARDBP. By generating patient-derived disease profiles, the team intends to identify therapeutic targets that could inform future patient care.
Timeline
The research collaboration between Merck & Co and Mayo Clinic was initiated earlier in 2026.
The Tech Race
This collaboration follows a pattern of specialized research alliances established by the Mayo Clinic to leverage patient-derived data for drug discovery. It positions Transcripta Bio to compete in the precision medicine sector by utilizing transcriptomic platforms to map complex genetic diseases.
While the research is in the discovery phase, the collaboration aims to provide a path toward more effective, targeted treatments for ALS patients. Individuals participating in the study contribute to a database that could eventually yield breakthroughs in neurodegenerative disease care.
The takeaway
This partnership highlights the industry shift toward using patient-specific molecular data to drive drug discovery. Targeted genomic analysis remains a key focus for researchers aiming to move beyond one-size-fits-all treatments for neurodegenerative conditions.
Further reading
For more on the latest developments in medical innovation, visit the Biotech section.
Source note: This article includes information reported by Pharmaceutical Technology.
Live Poll
Should medical research prioritize AI-driven drug discovery for rare neurodegenerative diseases?
